Search results “David sabatini cancer research”
Signaling Pathways in Cancer Symposium: David Sabatini
David Sabatini Whitehead Institute “Growth By The mTOR Pathway” https://ki.mit.edu/news/pathways/2012
Views: 4031 KochInstituteMIT
Dr. David Sabatini's Research on the mTOR Pathway
The FNIH selected David M. Sabatini, M.D., Ph.D., as the recipient of the 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to nutrients. Learn about Dr. Sabatini's work on nutrient sensing and the impact of caloric restriction on health and lifespan. Dr. Sabatini is a Member of the Whitehead Institute for Biomedical Research, a Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute.
Views: 2357 FNIH
2011 KI Symposium: David Sabatini (Part 1 of 2)
Part 1 of David Sabatini's talk, "mTOR Signaling and Cancer Metabolism," presented at the 2011 Koch Institute Summer Symposium.
Views: 5123 KochInstituteMIT
3rd de Duve Lecture - D. Sabatini: mTOR and lysosomes in growth control
given by Prof. David Sabatini (Cambridge, MA, USA) on March 1, 2018
Views: 825 de Duve Institute
David Sabatini, Ph D , M D , Growth By The mTOR Pathway
David Sabatini, Ph.D., M.D. of the Whitehead Institute at MIT discussed his work defining the role of mTOR in the amino acid sensing pathway.
2011 Summer Symposium: David Sabatini
mTOR signaling and cancer metabolism David Sabatini, Whitehead Institute https://ki.mit.edu/news/symposium/2011
Views: 213 KochInstituteMIT
2011 KI Symposium: David Sabatini (Part 2 of 2)
Part 2 of David Sabatini's talk, "mTOR Signaling and Cancer Metabolism," presented at the 2011 Koch Institute Summer Symposium.
Views: 1955 KochInstituteMIT
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
David Sabatini, Member, Whitehead Institute "Cancer: Treating the "Untreatable" Part II"
Confronting the complexity of targeting the PI3K/AKT/mTOR pathway in cancer
Panellists discuss different aspects important for rational clinical development of PI3K/AKT/mTOR inhibitors: what can we learn from studying biomarkers and resistance mechanisms? How can we build on this knowledge? http://www.esmo.org Video produced by the European Society for Medical Oncology (ESMO)
Promise, Progress and Politics of Cancer Research - Harold Varmus
Nobel Laureate Harold Varmus delivered his lecture 'Promise, Progress and Politics of Cancer Research' at Institut Curie in Paris. Dr Varmus visited Paris in May 2016 as part of the Nobel Prize Inspiration Initiative. Through the Initiative, Nobel Laureates give career advice for young scientists, explain their discoveries and give insights into life after the Nobel Prize. To hear more insights from Nobel Laureates please subscribe to our YouTube channel or visit www.nobelprizeii.org.
Views: 536 NobelPrizeII
The PI3K Signaling Pathway
Genentech BioOncology is currently conducting research on how PI3K Kinase signaling pathway is critical to cell survival and cell growth. Learn how the PI3K pathway involves an intricate signaling cascade that is among the most frequently activated pathways in cancer.
Views: 64189 Genentech
Regulation of growth by the mTOR pathway
Regulation of growth by the mTOR pathway Air date: Wednesday, March 20, 2013, 3:00:00 PM Wednesday Afternoon Lecture Series The mammalian target of rapamycin (mTOR), the target of the immunosuppressive drug rapamycin, is the central component of a nutrient- and hormone-sensitive signaling pathway that regulates cell growth and proliferation. This pathway becomes deregulated in many human cancers and plays an important role in the control of metabolism and aging. Sabatini's lab has identified two distinct mTOR-containing proteins complexes, one of which regulates growth through S6K and another that regulates cell survival through Akt. These complexes, mTORC1 and mTORC2, define both rapamycin-sensitive and insensitive branches of the mTOR pathway. New results on the regulation and functions of the mTORC1 and mTORC2 pathways will be discussed. Author: David M. Sabatini, M.D., Ph.D., MIT Runtime: 00:59:04 Permanent link: http://videocast.nih.gov/launch.asp?17962
Views: 45195 nihvcast
mTOR Signaling Pathway: mTOR Complexes, Regulation and Downstream effects
An in-depth lesson on mTOR signaling pathway, looking at both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), a brief overview of the regulation of the mTOR pathway and the many (many) downstream effects of the mTOR pathway. Hey guys! In this lesson I give you an in-depth, detailed analysis of the mTOR pathway, starting with what the mTOR complexes are composed of, the intricate regulation of the mTOR pathway and what the mTOR pathway does including up regulation of protein synthesis and suppression of protein degradation. WARNING: This video is not for the faint of heart - there is a lot of information in this video! Hope you all find it helpful. ---------------------------------------------------------------------------------------------------- For books and other supplemental information on these topics, please check out my Amazon Affiliate Page ➜ https://www.amazon.com/shop/jjmedicine Support future lessons and lectures ➜ https://www.patreon.com/jjmedicine Follow me on Twitter! ➜ https://twitter.com/JJ_Medicine
Views: 16400 JJ Medicine
“The Where and Why of the mTOR pathway”
Brian Kennedy, PhD Professor Buck Institute for Research on Aging Novato, CA Lecture: “The Where and Why of the mTOR pathway”
30. Cancer 2
MIT 7.013 Introductory Biology, Spring 2011 View the complete course: http://ocw.mit.edu/7-013S11 Instructor: Tyler Jacks In this lecture, Professor Jacks discusses the genes and mutations involved in the development of cancer, how to find them, and why they are important. License: Creative Commons BY-NC-SA More information at http://ocw.mit.edu/terms More courses at http://ocw.mit.edu
Views: 13863 MIT OpenCourseWare
2017 FNIH Award Ceremony: Presenting the Lurie Prize in Biomedical Sciences
Join us on Wednesday, May 17, 2017 for the FNIH Award Ceremony and presentation of the 5th annual Lurie Prize in Biomedical Sciences to Dr. David Sabatini, Member of the Whitehead Institute for Biomedical Research. To learn more visit www.FNIH.org/AwardCeremony. This $100,000 award, made possible by a generous gift from FNIH Board member Ann Lurie, recognizes outstanding achievement by a promising young scientist in biomedical research. The evening’s Master of Ceremonies is award-winning journalist and television news anchor Wolf Blitzer.
Views: 242 FNIH
Whitehead Institute: How to boost the efficacy of the chemotherapy drug methotrexate
Naama Kanarek, a postdoctoral researcher in the lab of Whitehead Member David Sabatini, explains how new genetic tools are allowing insights into the sensitivity of cancer cells to methotrexate.
2016 Killian Lecture: Tyler Jacks, "Unlocking the Secrets of Cancer"
Lecture title: "Unlocking the Secrets of Cancer" Tyler Jacks, the David H. Koch professor of biology and director of the Koch Institute for Integrative Cancer Research, was MIT’s James R. Killian Jr. Faculty Achievement Award winner for 2015–2016. A pioneering cancer biologist, Professor Jacks was recognized by the committee for his influence on the field of cancer research and for his leadership of MIT’s multidisciplinary cancer research community. Thursday, February 11, 2016 4 pm Huntington Hall (10-250)
Views: 1544 MIT Institute Events
Essay Winner Highlights Importance of Communication in Science
Liron Bar-Peled, winner of the 2014 Science and SciLifeLab Grand Prize for his essay "Size Does Matter," speaks on the importance of communication in science and his work at The Scripps Research Institute (TSRI)—basic research with relevance to cancer. Bar-Peled, whose essay grew out of his graduate work in the lab of David Sabatini at MIT, is currently Lallage Feazel Wall Fellow of the Damon Runyon Cancer Research Foundation at TSRI. Click [CC] in video viewer to access Closed Captions and Subtitles on any of our videos.
Views: 699 Scripps Research
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Hazel Sive, Member, Whitehead Institute "An Introduction to the Importance of Basic Research"
The PI3K / AKT / mTOR Pathway Part 1
In this video we discuss the PI3K / AKT / mTOR pathway and its involvement in cancer.
Views: 8853 Ben1994
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Lyerka Miller introduces Whitehead Director David C. Page
Whitehead Institute: Reducing the toxicity of the chemotherapy drug methotrexate
Naama Kanarek, a postdoctoral researcher in the lab of Whitehead Member David Sabatini, discusses some of the challenges of methotrexate chemotherapy treatment and how research might help address these challenges.
Dr. David Sabatini - Conferencia IDIBELL 2012, Barcelona.
El Dr. David Sabatini habla con ecancer en la Conferencia de IDIBELL en Medicina Personalizada. Explica el uso de la rapimicina y su implicación en el sistema de "MTor Pathway". Para mayor información visite http://www.ecancerlatinoamerica.org
ROBERT A. WEINBERG, PhD - EMT, Cancer Stem Cells and the Mechanisms of Malignant Progression
Winner of the Salk Institute Medal for Research Excellence An internationally recognized authority on the genetic basis of human cancer, Robert A. Weinberg is a founding member of the Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research at the Massachusetts Institute of Technology (MIT). In 1992, he earned the Gairdner Foundation International Award for Achievements in Medical Science. He is also a recipient of the National Medal of Science, the Wolf Prize and the Breakthrough Prize in Life Sciences. He is the first Director of the Ludwig Cancer Center at MIT. Over the past three decades, Weinberg has made breakthrough discoveries in the molecular and genetic roots of cancers. His lab discovered the first oncogene in 1982 and the first tumor suppressor gene in 1986. Most recently, Weinberg and his colleagues were the first to define the genetic hallmarks that a normal human cell must acquire to be transformed into a human cancer cell.
Views: 9602 Salk Institute
Macroautophagy | Regulation During Feeding, Fasting and Starvation
Lesson on macroautophagy and regulation by fasting and starvation, with an additional detailed overview of how macroautophagy is inhibited during feeding and the fed state. Macroautophagy is a nutrient responsive process and is inhibited during feeding and the fed state when nutrient and energy levels are high. During short-term fasting, macroautophagy becomes activated by AMPK, and inhibition of mTOR leads to further activation of macroautophagy and activation of transcription factor EB (TFEB), which is the master regulator of lysosomal biogenesis and autophagy. Hey everyone. Here is another lesson on macroautophagy. This is a continuation of the "Autophagy: Introduction to Macroautophagy" lesson, and further elaborates on how macroautophagy is regulated, in particular by nutrient status of the cell including the fed state, and fasting and starvation. We also briefly introduce the idea of a chronological differentiated activation during fasting of different proteolytic systems with acute activation of the ubiquitin proteasome system, macroautophagy activation within 4 hours of fasting and chaperone-mediated autophagy activation within 12 hours of fasting. We will discuss this topic further in a future lesson. Before watching this lesson, please check out this introductory lesson on Macroautophagy: https://www.youtube.com/watch?v=UmSVKzHc5yA For more information on Chaperone-mediated autophagy (CMA), please check out this lesson: https://www.youtube.com/watch?v=M5kr1W8sWV0 For an in-depth review of the mTOR signaling pathway, please check out this lesson: https://www.youtube.com/watch?v=-2pXbSpDPQE ---------------------------------------------------------------------------------------------------------- For books and other supplemental information on these topics, please check out my Amazon Affiliate Page ➜ https://www.amazon.com/shop/jjmedicine Support future lessons and lectures ➜ https://www.patreon.com/jjmedicine Follow me on Twitter! ➜ https://twitter.com/JJ_Medicine
Views: 2757 JJ Medicine
2015 Whitehead Symposium :: Cancer: Treating the "Untreatable"
Richard Young, Member, Whitehead Institute "Cancer: Treating the "Untreatable" Part I"
Conquering Cancer: Personalized Cancer Care
Session Chair: Michael B. Yaffe, David H. Koch Institute for Integrative Cancer Research at MIT; Professor, Departments of Biology and Biological Engineering, MIT; Senior Associate, Broad Institute Panel: Daniel A. Haber SB '77 SM '77, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor, Harvard Medical School; Investigator, Howard Hughes Medical Institute Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT; Latham Family Career Development Assistant Professor of Biology, MIT David M. Livingston, Emil Frei Professor of Genetics and Medicine, Harvard Medical School; Deputy Director, Dana-Farber/Harvard Cancer Center; Chief, Charles A. Dana Division of Human Cancer Genetics Corbin Elizabeth Meacham, G, David H. Koch Institute for Integrative Cancer Research at MIT; Department of Biology, MIT
Signaling Pathways in Cancer Symposium: Michael Yaffe
Michael Yaffe David H. Koch Institute for Integrative Cancer Research at MIT “Harnessing Cross-Talk Between Signaling Pathways to Improve Cancer Treatment” https://ki.mit.edu/news/pathways/2012
Views: 351 KochInstituteMIT
Michael Hall (University of Basel): The Story of TOR (Target of Rapamycin)
https://www.ibiology.org/cell-biology/target-rapamycin/ Michael Hall describes the discovery of TOR (Target of Rapamycin) protein, the key controller of the size of both individual cells and entire organisms.   Talk Overview: TOR, the Target of Rapamycin, is now known to be a central controller of cell, tissue and organism growth and an important molecule in many human diseases including cancer, cardiac hypertrophy, diabetes and obesity.  Michael Hall explains how the fortuitous decision, in 1991, to investigate the action of rapamycin in yeast, led to the discovery of TOR. Speaker Biography: Dr. Michael Hall received his PhD from Harvard and was a post-doctoral fellow at the Institut Pasteur and the University of California, San Francisco.  He joined the Biozentrum of the University of Basel in 1987 and where he is currently a Professor of Biochemistry. Hall’s lab continues to study TOR and its role in development, aging and disease. Hall has received numerous awards in recognition of his pioneering work.  Recent honors include the Louis-Jeantet Prize for Medicine (2009), the Marcel Benoist Prize (2012), the Breakthrough Prize (2014), the Canada Gairdner Award (2015), and the Albert Lasker Basic Medical Research Award (2017).  Hall is also a member of the US National Academy of Sciences. Learn more about Dr. Hall’s research here: https://www.biozentrum.unibas.ch/research/groups-platforms/overview/unit/hall/
Tyler Jacks, Director, David H. Koch Institute for Integrative Cancer Research
2008 Koch Institute Symposium: Introduction given by the Institute's Director Tyler Jacks.
Views: 691 KochInstituteMIT
Black Cat by D. Sabatini at Sister Wicked Open Mic, Sept 2017
Black Cat, an original by David Sabatini performed at Sister Wicked Open Mic, Sept 30, 2017
Killing cancer cells by targeting glucose metabolism
Cristina Muñoz Pinedo. Cell Death Regulation Group IDIBELL (Institut d'Investigació Biomèdica de Bellvitge) Oncogenic transformation promotes metabolic changes which makes tumors "addicted" to certain metabolites. For this reason, inhibition of tumor metabolism is a promising new therapeutic approach. However, little is known about how metabolic stress triggers tumor cell death. Glucose depletion has been shown to kill cells either by necrosis (non-apoptotic, pro-inflamatory cell death) or by the mitochondrial pathway of apoptosis. Our studies indicate that several tumor cell lines of different origins die in a non-apoptotic manner when deprived of glucose. However, we have recently described an atypical apoptotic pathway engaged in cells from solid tumors. Surprisingly, apoptosis induced by glucose deprivation is independent of the Bcl-2-regulated mitochondrial pathway. We will describe this apoptotic pathway mediated by caspase-8, which is the initiator caspase engaged by death receptors of the TNF family. 2-deoxyglucose is a non-metabolizable glucose analog which competes with glucose and has shown anti-tumor effects in animals. Moreover, this compound is been tested in clinical trials. We are currently studying sensitivity of tumor cells, especially sarcoma cell lines, to 2-deoxyglucose. Interestingly, 2-deoxyglucose promoted apoptosis in cell lines in which glucose deprivation promoted necrosis, suggesting different death mechanisms. 2-deoxyglucose activates the mitochondrial apoptotic pathway and regulates several apoptotic proteins in p53-deficient cells. We found death under normoxia to be associated to endoplasmic reticulum stress rather than lack of ATP. We will discuss the signaling pathways involved in responses to nutritional stress and how to improve sensitivity of tumor cells to metabolic targeting.
The Edge of Medicine and Ageing - David Sinclair
Before the 1990’s, old age was seen as an unavoidable fact of life; like an old car, we just wear out. Since then we’ve addressed ageing like a set of fixable parts. When an organ breaks down, we medicate it or replace it. When cancer appears we seek to eradicate it. David Sinclair doesn’t want you to think that way. Speaking at Amplify, David described ageing as something we can prevent, and in doing so, avoid the diseases that we become more vulnerable to. According to David, when we successfully eradicate cancer, we only extend someone’s lifespan by 2.3 years, because in an ageing body, another organ is nearing expiry. AMP’s Amplify innovation and ideas program is Australia’s leading business and innovation platform for exploring technology, thought leadership and customer experience with some of the world’s boldest thinkers. For more information on this talk, head to https://www.amp.com.au/amplify/amplify-insights/david-sinclair-the-edge-of-medicine-and-ageing
Views: 21874 AMPAMPLIFY
Got Water?
We visit with David Sabatini from the Water Institute at the University of Oklahoma about the changes humanity could face due to water shortages over the next fifty years.
Views: 57 OklahomaHorizonTV
Tim Ferriss #193 ★ MY LIFE EXTENSION PILGRIMAGE TO EASTER ISLAND ★ The Tim Ferriss Show Timothy Ferriss (born July 20, 1977) is an American author, entrepreneur, self proclaimed "human guinea pig", and public speaker. He has written a number of self help books on the "4 hour" theme, some of which have appeared on the New York Times, Wall Street Journal, and USA Today bestseller lists, starting with The 4 Hour Workweek. Ferriss is also an angel investor and an advisor to Facebook, Twitter, StumbleUpon, Evernote, and Uber, among other companies. ╔═══════════════════════════════════╗ ║We do not own this Video. This video was created by using ║Tim Ferriss Show's Audio source to remade and resound in order to promote and expand his name to Audiences all over America ║Please visit his Blog to explore more things he could bring to you via: https://goo.gl/MVEDLo ║Just spreads his show to everyone! ║Thank you so much!
2010 KI Symposium: Eric Lander (Part 1 of 3)
Part 1 of Eric Lander's talk, "The Human Genome and Cancer," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 2038 KochInstituteMIT
Submitted by Mishael Khan
2012 Koch Institute Symposium: Introductory Remarks
Introductory remarks by Director Tyler Jacks at the 2012 Summer Symposium on Epigenetics, Plasticity and Cancer at the Koch Institute for Integrative Cancer Research at MIT. http://ki.mit.edu/news/symposium
Views: 150 KochInstituteMIT
2016 Whitehead Symposium: Part 3
Keynote by David C. Page, MD
Prof David Kwiatkowski discusses recent developments in understanding kidney cancer genetics
At the Thirteenth International Kidney Cancer Symposium, Prof David Kwiatkowski (Brigham and Women's Hospital, MA) discusses targeting the mTOR pathway in kidney cancer treatment. It may be clinically necessary to target different proteins, mTOR, TSC1 and TSC2, of the mTOR pathway. Mutations in genes encoding for these proteins correlate with therapeutic response, and this may influence clinical trial design and provide the basis for personalised medicine in kidney cancer.
2010 KI Symposium: David Raulet (Part 1 of 3)
Part 1 of David Raulet's talk, "Recognition of Cancer Cells by Natural Killer Cells," presented at the 2010 Koch Institute Summer Symposium. http://ki.mit.edu
Views: 400 KochInstituteMIT
2011 KI Symposium: M. Celeste Simon (Part 1 of 3)
Part 1 of M. Celeste Simon's talk, "HIFs, Myc, and Metabolism," presented at the 2011 Koch Institute Summer Symposium.
Views: 926 KochInstituteMIT
Building Bridges Symposium, May 2014: Vander Heiden/ Cahill
Targeting Mutant IDH1 in Malignant Gliomas Matthew Vander Heiden of the Koch Institute William Kaelin of the Dana-Farber Cancer Institute Daniel Cahill of Massachusetts General Hospital https://ki.mit.edu/news/bridge/2014/symposium
Views: 148 KochInstituteMIT
What Can Fat Cells Teach Us About Cancer?
Dana-Farber Cancer Institute's Bruce Spiegelman, PhD, explains the importance of fat cell differentiation, energy metabolism and the potential implications of his research for the treatment of cancer.
2013 Summer Symposium: Dane Wittrup
Synergism Between Antibody and T Cell-Mediated Cancer Immunotherapy K. Dane Wittrup Associate Director, Koch Institute for Integrative Cancer Research Carbon P. Dubbs Professor of Chemical Engineering and Bioengineering Massachusetts Institute of Technology https://ki.mit.edu/news/symposium/2013
Views: 160 KochInstituteMIT